A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
This study is testing a new experimental medication called AZD1390 combined with radiation therapy for adults with aggressive brain tumors. Researchers want to see how safe this combination is and how the body handles the new medicine.
This trial is for adults with a confirmed diagnosis of certain aggressive brain tumors, such as glioblastoma. Participants must be able to care for most of their personal needs and meet specific medical and health history requirements.
Participants will receive the investigational drug AZD1390 alongside radiation therapy to treat their brain tumor. Doctors will closely monitor their safety, track how the drug moves through the body, and perform regular brain scans.
This study takes place at medical centers in locations including Boston and New York. The study is currently active but is not looking for new participants at this time.
- 1Tests a new brain tumor drug called AZD1390 combined with radiation.
- 2Designed primarily to check the safety and side effects of the treatment.
- 3Currently active at select locations in the United States, though not recruiting new patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.